全球就开发COVID-19病毒疫苗展开合作

▲全球视野 本土思考

★专业/深度/睿见资讯尽在医疗旅游

防疫创新联盟（Coalition for Epidemic Preparedness Innovations-CEPI）和全球制药巨头葛兰素史克（GSK）建立了新的合作伙伴关系，旨在帮助全球为COVID-19开发疫苗。

CEPI还与CureVac，Inovio，Moderna和美国国家过敏和传染病研究所合作。但是，这需要时间。

GSK将提供其已建立的大流行疫苗佐剂平台技术，以增强针对COVID-19的有效疫苗的开发。

GSK是使用不同佐剂系统开发创新疫苗的领导者。将佐剂添加到某些疫苗中以增强免疫反应，从而比单独的疫苗产生更强，更持久的抗感染免疫力。在大流行情况下，佐剂的使用尤为重要，因为它可以减少每剂所需的抗原量，从而可以生产更多的疫苗剂量并提供给更多的人。

将GSK的佐剂系统与CEPI资助的开创性平台技术结合起来，有可能通过降低保护每个个体所需的疫苗抗原剂量，更迅速地提供更多疫苗。这种节省抗原的效果使特定的疫苗供应更进一步，增加了受益的人数。

CEPI将协调GSK和由CEPI资助的实体之间的接触，这些实体有兴趣使用GSK的佐剂技术测试其疫苗平台，以开发针对2019-nCoV的有效疫苗。葛兰素史克与澳大利亚昆士兰大学之间签署了第一个正式形式的协议，该协议与CEPI达成了合作，以开发分子钳制疫苗平台，旨在针对多种病毒病原体进行针对性的快速疫苗生产。

昆士兰大学的研究团队正在推进2019年nCoV疫苗计划，GSK佐剂的可用性将使其能够进行重要的临床前试验，以评估疫苗的有效性。

CEPI还与CureVac，Inovio，Moderna和美国国家过敏和传染病研究所合作。这些伙伴关系旨在增进人们对新型冠状病毒的科学认识，并开发针对该新型冠状病毒的疫苗。这些计划将利用CEPI已经支持的快速反应平台，以期尽快将2019-nCoV疫苗候选者推进临床测试。

CEPI寻求其他合作伙伴，以快速开发和制造可用于新的冠状病毒的已验证疫苗技术。

冠状病毒是可以导致呼吸系统疾病的病毒家族，包括中东呼吸综合征（MERS-CoV）和严重急性呼吸综合征（SARS-CoV）。冠状病毒在动物和人之间传播，并且可以进化为人类先前未发现的病毒株。＊

COVID-19: Global collaboration to develop coronavirus vaccine

CEPI, the Coalition for Epidemic Preparedness Innovations, and global pharma giant GSK have a new collaboration aimed at helping the global effort to develop a vaccine for COVID-19. CEPI, is also working with CureVac, Inovio, Moderna, and the U.S. National Institute of Allergy and Infectious Diseases. It will take time, however.

GSK will make its established pandemic vaccine adjuvant platform technology available to enhance the development of an effective vaccine against COVID-19.

GSK is a leader in the development of innovative vaccines using different adjuvant systems. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer-lasting immunity against infections than the vaccine alone. The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and made available to more people.

Coupling GSK’s adjuvant systems with the pioneering platform technology CEPO is funding has the potential to make more vaccine available more rapidly, by decreasing the dose of vaccine antigen required to protect each individual. This antigen-sparing effect makes a given supply of vaccine go farther, increasing the number of people who can benefit.

CEPI will coordinate engagements between GSK and entities funded by CEPI who are interested in testing their vaccine platform with GSK’s adjuvant technology to develop effective vaccines against 2019-nCoV. The first agreement to formalise this arrangement has been signed between GSK and the University of Queensland, Australia, which has a partnering agreement with CEPI to develop a molecular clamp vaccine platform, intended to enable targeted and rapid vaccine production against multiple viral pathogens.

The research team at The University of Queensland are progressing a 2019-nCoV vaccine programme and the availability of the GSK adjuvant will enable it to carry out important pre-clinical experiments designed to assess vaccine effectiveness.

CEPI, is also working with CureVac, Inovio, Moderna, and the U.S. National Institute of Allergy and Infectious Diseases. These partnerships seek to improve the scientific understanding of the novel coronavirus and to develop vaccines against it. These programmes will leverage rapid response platforms already supported by CEPI with the aim of advancing 2019-nCoV vaccine candidates into clinical testing as quickly as possible.

CEPI seeks additional partners to rapidly develop and manufacture already proven vaccine technology that can be used against the new coronavirus.

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (2019-nCoV) was identified as the cause of pneumonia cases in Wuhan City, Hubei Province of China, and additional cases have since then been found in a number of countries, which so far can all be traced back to Wuhan City, China.